专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5869636A Immunoreactive peptide sequence from a 43 kD human cancer antigen 失效
标题翻译：来自43kD人癌抗原的免疫反应性肽序列
公开(公告)号：US5869636A
公开(公告)日：1999-02-09
申请号：US602864
申请日：1996-02-28
申请人： Reiko F. Irie , Takanori Oka
发明人： Reiko F. Irie , Takanori Oka
IPC分类号： C12N15/02 , A61K35/26 , A61K38/00 , A61K38/45 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/04 , C07H21/04 , C07K14/47 , C07K16/30 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/04 , C12P21/08 , C12R1/19 , C12R1/91 , C07H21/02 , C12Q1/48 , C12Q1/54
CPC分类号： C07K14/4748 , C07K14/47 , C07K16/3053 , A61K2039/505 , A61K38/00 , A61K39/00 , C07K2317/21 , C07K2317/34 , C07K2319/00
摘要： A recombinant cell line expressing a polypeptide with the amino acid sequence -Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile- has been isolated. The cell line was described as a recombinant E. coli strain. Isolated purified polypeptide include 10 or less amino acid sequences to a length of less than 100 amino acid sequences. The polypeptide is further defined as including the amino acid sequence of beta-galactosidase or glutathione-S-transferase.
摘要翻译： PCT No.PCT / US94 / 09798 Sec。 371日期：1996年4月29日 102（e）日期1996年4月29日PCT 1994年8月30日PCT PCT。公开号WO95 / 06725 日期1995年3月9日已经分离了表达具有氨基酸序列-Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-的多肽的重组细胞系。细胞系被描述为重组大肠杆菌菌株。分离的纯化多肽包括长度小于100个氨基酸序列的10个或更少的氨基酸序列。该多肽被进一步定义为包括β-半乳糖苷酶或谷胱甘肽-S-转移酶的氨基酸序列。

2. 发明授权

US06288035B1 Method of treating cancer with a 43 kD human cancer antigen 有权
标题翻译：用43kD人类癌症抗原治疗癌症的方法
公开(公告)号：US06288035B1
公开(公告)日：2001-09-11
申请号：US09504410
申请日：2000-02-15
申请人： Reiko F. Irie , Takanori Oka
发明人： Reiko F. Irie , Takanori Oka
IPC分类号： A61K3800
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K14/47 , C07K16/3053 , C07K2317/21 , C07K2317/34 , C07K2319/00
摘要： A tumor associated protein has been discovered to exhibit immunoreactivity to human monoclonal antibody L92. A ten amino acid peptide segment of the protein and a fourteen amino acid peptide which contains the ten amino acid peptide has also been isolated and exhibits immunoreactivity to the same antibody. Using truncated fusion proteins, the minimum recognition site for antibody binding was determined to be four amino acids. Also disclosed are polypeptide compositions against human tumors that includes the polypeptides or protein of the present disclosure, as well as antibodies reactive with these polypeptides that may be employed directly for treatment or diagnosis. A certain embodiment of the present invention is also the DNA sequence encoding the ten amino acid peptide and the DNA encoding the fourteen amino acid peptide which also exhibits immunoreactivity to human monoclonal antibody L92 and cytotoxic T cells.
摘要翻译：已经发现肿瘤相关蛋白对人单克隆抗体L92表现出免疫反应性。蛋白质的十个氨基酸肽段和含有十个氨基酸肽的十四个氨基酸肽也已被分离，并显示出对相同抗体的免疫反应性。使用截短的融合蛋白，测定抗体结合的最小识别位点为四个氨基酸。还公开了包含本公开的多肽或蛋白质的人肿瘤的多肽组合物，以及可直接用于治疗或诊断的与这些多肽反应的抗体。本发明的某个实施方案也是编码十个氨基酸肽的DNA序列和编码与人单克隆抗体L92和细胞毒性T细胞具有免疫反应性的十四个氨基酸肽的DNA。

3. 发明授权

US6077950A Methods for enhancing an immune response from a 43 KD human cancer antigen 失效
标题翻译：增强43KD人类癌症抗原免疫应答的方法
公开(公告)号：US6077950A
公开(公告)日：2000-06-20
申请号：US247146
申请日：1999-02-09
申请人： Reiko F. Irie , Takanori Oka
发明人： Reiko F. Irie , Takanori Oka
IPC分类号： C12N15/02 , A61K35/26 , A61K38/00 , A61K38/45 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/04 , C07H21/04 , C07K14/47 , C07K16/30 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/04 , C12P21/08 , C12R1/19 , C12R1/91 , A61K38/04
CPC分类号： C07K14/4748 , C07K14/47 , C07K16/3053 , A61K2039/505 , A61K38/00 , A61K39/00 , C07K2317/21 , C07K2317/34 , C07K2319/00
摘要： A tumor associated protein has been discovered to exhibit immunoreactivity to human monoclonal antibody L92. A ten amino acid peptide segment of the protein and a fourteen amino acid peptide which contains the ten amino acid peptide has also been isolated and exhibits immunoreactivity to the same antibody. Using truncated fusion proteins, the minimum recognition site for antibody binding was determined to be four amino acids. Also disclosed are polypeptide compositions against human tumors that includes the polypeptides or protein of the present disclosure, as well as antibodies reactive with these polypeptides that may be employed directly for treatment or diagnosis. A certain embodiment of the present invention is also the DNA sequence encoding the ten amino acid peptide and the DNA encoding the fourteen amino acid peptide which also exhibits immunoreactivity to human monoclonal antibody L92 and cytotoxic T cells.
摘要翻译：已经发现肿瘤相关蛋白对人单克隆抗体L92表现出免疫反应性。蛋白质的十个氨基酸肽段和含有十个氨基酸肽的十四个氨基酸肽也已被分离，并显示出对相同抗体的免疫反应性。使用截短的融合蛋白，测定抗体结合的最小识别位点为四个氨基酸。还公开了包含本公开的多肽或蛋白质的人肿瘤的多肽组合物，以及可直接用于治疗或诊断的与这些多肽反应的抗体。本发明的某个实施方案也是编码十个氨基酸肽的DNA序列和编码与人单克隆抗体L92和细胞毒性T细胞具有免疫反应性的十四个氨基酸肽的DNA。

4. 发明授权

US5419904A Human B-lymphoblastoid cell line secreting anti-ganglioside antibody 失效
标题翻译：人类B淋巴母细胞系分泌抗神经节苷脂抗体
公开(公告)号：US5419904A
公开(公告)日：1995-05-30
申请号：US26320
申请日：1993-02-26
申请人： Reiko F. Irie
发明人： Reiko F. Irie
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/30 , C07K16/42 , C12N5/10 , C12N5/22 , C12P21/08 , C12R1/91 , C07K16/18
CPC分类号： C07K16/3053 , C07K16/4266 , A61K38/00
摘要： A human B-lymphoblastoid cell line which is identified as L612. The L612 cell line is an Epstein-Barr virus transformed cell line which secretes a human monoclonal antibody (L612) which is reactive with glycoconjugates having an epitope of terminal NeuAc .alpha.2-3 Galactose residue such as GM3 and GM4 present on a variety of human tumor tissues. The L612 antibody is useful in treating patients with the epitope containing tumors and is also useful in raising anti-id antibodies for use as surrogate antigens and diagnostic reagents.
摘要翻译：人类B淋巴母细胞细胞系被鉴定为L612。 L612细胞系是分泌人单克隆抗体（L612）的爱泼斯坦 - 巴尔病毒转化细胞系，其与具有末端NeuAcα2-3表位的糖缀合物反应，所述糖缀合物具有存在于各种人类上的NeuAcα2-3半乳糖残基如GM3和GM4 肿瘤组织。 L612抗体可用于治疗含有表位的肿瘤患者，并且也可用于提高用作替代抗原和诊断试剂的抗id抗体。

5. 发明授权

US4557931A Antigenic compositions and methods for using same 失效
标题翻译：抗原组合物及其使用方法
公开(公告)号：US4557931A
公开(公告)日：1985-12-10
申请号：US446231
申请日：1982-12-02
申请人： Reiko F. Irie , Tadashi Tai , Donald L. Morton , Leslie D. Cahan , James C. Paulson
发明人： Reiko F. Irie , Tadashi Tai , Donald L. Morton , Leslie D. Cahan , James C. Paulson
IPC分类号： A61K9/127 , A61K39/00 , G01N33/574
CPC分类号： A61K9/1271 , A61K39/0011 , G01N33/574 , G01N33/57469 , A61K2039/6081 , Y10S435/96 , Y10S435/961
摘要： GM2 is a ganglioside present on the surface of tumors and stimulates an appreciable immune response in mammals. It is useful when coupled with a non-toxic protein carrier or mixed with an adjuvent and injected parenterally of raising the anti-GM2 titer in serum. GM2 is also valuable as a diagnostic agent.
摘要翻译： GM2是存在于肿瘤表面的神经节苷脂，并且在哺乳动物中刺激明显的免疫应答。当与无毒蛋白质载体偶联或与佐剂混合并且肠胃外注射以提高血清中的抗GM2滴度时，它是有用的。 GM2也作为诊断剂有价值。

6. 发明授权

US5705159A Immunoreactive peptide sequence from a 43 KD human cancer antigen 失效
标题翻译：来自43KD人癌症抗原的免疫反应性肽序列
公开(公告)号：US5705159A
公开(公告)日：1998-01-06
申请号：US190801
申请日：1994-02-01
申请人： Reiko F. Irie , Takanori Oka
发明人： Reiko F. Irie , Takanori Oka
IPC分类号： C12N15/02 , A61K35/26 , A61K38/00 , A61K38/45 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/04 , C07H21/04 , C07K14/47 , C07K16/30 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/04 , C12P21/08 , C12R1/19 , C12R1/91 , C07K7/00 , C07K7/06
CPC分类号： C07K14/4748 , C07K14/47 , C07K16/3053 , A61K2039/505 , A61K38/00 , A61K39/00 , C07K2317/21 , C07K2317/34 , C07K2319/00
摘要： A tumor associated protein has been discovered to exhibit immunoreactivity to human monoclonal antibody L92. A ten amino acid peptide segment of the protein and a fourteen amino acid peptide which contains the ten amino acid peptide has also been isolated and exhibits immunoreactivity to the same antibody. Using truncated fusion proteins, the minimum recognition site for antibody binding was determined to be four amino acids. Also disclosed are polypeptide compositions against human tumors that includes the polypeptides or protein of the present disclosure, as well as antibodies reactive with these polypeptides that may be employed directly for treatment or diagnosis. A certain embodiment of the present invention is also the DNA sequence encoding the ten amino acid peptide and the DNA encoding the fourteen amino acid peptide which also exhibits immunoreactivity to human monoclonal antibody L92 and cytotoxic T cells.
摘要翻译：已经发现肿瘤相关蛋白对人单克隆抗体L92表现出免疫反应性。蛋白质的十个氨基酸肽段和含有十个氨基酸肽的十四个氨基酸肽也已被分离，并显示出对相同抗体的免疫反应性。使用截短的融合蛋白，测定抗体结合的最小识别位点为四个氨基酸。还公开了包含本公开的多肽或蛋白质的人肿瘤的多肽组合物，以及可直接用于治疗或诊断的与这些多肽反应的抗体。本发明的某个实施方案也是编码十个氨基酸肽的DNA序列和编码与人单克隆抗体L92和细胞毒性T细胞具有免疫反应性的十四个氨基酸肽的DNA。

7. 发明授权

US5208146A Murine monoclonal anti-idiotype antibodies 失效
标题翻译：鼠单克隆抗独特型抗体
公开(公告)号：US5208146A
公开(公告)日：1993-05-04
申请号：US609255
申请日：1990-11-05
申请人： Reiko F. Irie
发明人： Reiko F. Irie
IPC分类号： A61K39/00 , C07K16/42
CPC分类号： C07K16/4266 , A61K39/00 , Y10S530/809
摘要： Murine monoclonal anti-idiotype antibodies raised against a human monoclonal anti-ganglioside antibody identified as L612. Both alpha and beta type anti-idiotype antibodies are disclosed which belong to the IgG1 class and contain kappa light chains. Two hybridoma cell lines which produced the monoclonal anti-idiotype antibodies are identified. The beta-type anti-idiotype antibodies are useful as an immunization agent to raise antibodies which are immunoreactive with tumors. The alpha-type anti-idiotype antibodies are useful as a probe for use in detecting human monoclonal antibodies bound to biopsied tumor tissues and to identify expression of ganglioside antigens on biopsied human tissues.
摘要翻译：针对被证明为L612的人单克隆抗神经节苷脂抗体产生的鼠单克隆抗独特型抗体。公开了属于IgG1类并含有κ轻链的α型和β型抗独特型抗体。鉴定了产生单克隆抗独特型抗体的两个杂交瘤细胞系。 β型抗独特型抗体可用作免疫剂以产生与肿瘤免疫反应的抗体。 α型抗独特型抗体可用作检测结合活组织检查的肿瘤组织的人单克隆抗体并鉴定神经节苷脂抗原在活检组织上的表达。

8. 发明授权

US5206270A Method of inhibiting melanoma cells 失效
标题翻译：抑制黑素瘤细胞的方法
公开(公告)号：US5206270A
公开(公告)日：1993-04-27
申请号：US846087
申请日：1992-03-05
申请人： Reiko F. Irie
发明人： Reiko F. Irie
IPC分类号： A61K31/195
CPC分类号： A61K31/195
摘要： A method of inhibiting melanoma cell proliferation in a mammal by administering to the mammal S-allylcysteine or a pharmaceutically acceptable salt thereof.
摘要翻译：通过向哺乳动物施用S-烯丙基半胱氨酸或其药学上可接受的盐来抑制哺乳动物黑素瘤细胞增殖的方法。

9. 发明授权

US5593822A IgG depleted serum preparations and methods for antibody production 失效
标题翻译： IgG耗竭的血清制剂和抗体生产方法
公开(公告)号：US5593822A
公开(公告)日：1997-01-14
申请号：US163186
申请日：1993-12-07
申请人： Qing S. Zeng , Reiko F. Irie
发明人： Qing S. Zeng , Reiko F. Irie
IPC分类号： C12N5/00 , C12P21/08 , A01N1/02 , C12P21/04
CPC分类号： C12N5/0018
摘要： A method for preparing serum depleted of IgG to be used in the production of IgG monoclonal antibodies is disclosed. Animal serum is contacted with protein G or protein A prior to addition to base media to obtain a superior cell culture medium depleted of serum derived IgG antibodies. Included in the disclosure are improved media preparations for cell culture of antibody producing cells and incorporating the antibody depleted serum and improved methods of producing the antibodies.
摘要翻译：公开了制备IgG单克隆抗体制备中用于制备血清贫血的方法。在加入到碱培养基中之前，动物血清与蛋白G或蛋白A接触以获得贫血血清IgG抗体的优良细胞培养基。本公开内容包括用于抗体产生细胞的细胞培养的改进的培养基制备物，并掺入抗体耗尽的血清和改良的产生抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式